AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: exenatide
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2008-05-06

Last Posted Date: 2015-02-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT00672399

Locations: 🇬🇧
Reseach Site, Derriford, Plymouth, United Kingdom
🇬🇧
Research Site, Leeds, West Yorkshire, United Kingdom

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386

Phase 2

Completed

Conditions: Pain

Interventions: Drug: AZD1386
Drug: Naproxen
Drug: Placebo

First Posted Date: 2008-05-06

Last Posted Date: 2012-06-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 103

Registration Number: NCT00672646

Locations: 🇺🇸
Research Site, Salt Lake City, Utah, United States

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: AZD0328
Drug: Placebo

First Posted Date: 2008-05-01

Last Posted Date: 2010-08-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 100

Registration Number: NCT00669903

Locations: 🇺🇸
Research Center, Glendale, California, United States

Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study

Completed

Conditions: Functional Psychoses
Informal Caregivers

First Posted Date: 2008-05-01

Last Posted Date: 2009-11-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 100

Registration Number: NCT00670371

Locations: 🇸🇪
Research Site, Stockholm, Sweden
🇸🇪
Research site, Bromma, Sweden

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Budesonide HFA
Drug: Budesonide CFC

First Posted Date: 2008-04-28

Last Posted Date: 2012-11-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 99

Registration Number: NCT00667992

Locations: 🇬🇧
Research Site, Perth, Scotland, United Kingdom

Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer

Completed

Conditions: Prostate Cancer

First Posted Date: 2008-04-28

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 214

Registration Number: NCT00668083

Locations: 🇮🇹
Research SIte, Firenze, Italy
🇮🇹
Research Site, Viareggio, Italy

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: saxagliptin
Drug: sitagliptin

First Posted Date: 2008-04-25

Last Posted Date: 2010-04-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 822

Registration Number: NCT00666458

Locations: 🇸🇪
Research Site, Umea, Sweden

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2008-04-22

Last Posted Date: 2017-02-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 631

Registration Number: NCT00663260

Locations: 🇺🇸
Marin Endocrine Care & Research, Inc., Greenbrae, California, United States
🇺🇸
Diabetes Medical Center Of California, Northridge, California, United States
🇺🇸
Office Of Richard Cherlin, Md, Los Gatos, California, United States

and more 32 locations

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Bladder Cancer
Urethra Cancer
Ureter Cancer
Renal Pelvis Cancer

Interventions: Drug: AZD4877

First Posted Date: 2008-04-18

Last Posted Date: 2011-01-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT00661609

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Saxagliptin
Drug: Metformin

First Posted Date: 2008-04-18

Last Posted Date: 2012-03-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 570

Registration Number: NCT00661362

Locations: 🇰🇷
Research Site, Uijeongbu-si, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy